Summary:
In patients with diabetic macular edema (DME) and elevated office systolic blood pressure (OSBP ≥ 140 mmHg), sodium-glucose cotransporter-2 inhibitor (SGLT2i; luseogliflozin) significantly reduced the number of intravitreal ranibizumab (IVR) injections required compared to sulfonylurea (glimepiride), though it was associated with no reported adverse events related to treatment but requires further confirmation in larger cohorts.
| PICO | Description |
|---|---|
| Population | Adults with diabetic macular edema (DME) and hypertension, defined as office systolic blood pressure ≥ 140 mmHg or a documented history of hypertension. |
| Intervention | Oral sodium-glucose cotransporter 2 inhibitor (SGLT2i), luseogliflozin, administered alongside standard intravitreal ranibizumab (IVR) therapy over a 48-week period. |
| Comparison | Oral sulfonylurea (glimepiride), administered similarly alongside IVR therapy during the same period. |
| Outcome | Patients receiving SGLT2i had significantly fewer IVR injections over 48 weeks (adjusted mean 3.3 ± 1.1 vs. 6.2 ± 1.0; p = 0.025), suggesting a reduced treatment burden. Office diastolic BP was also consistently lower in the SGLT2i group. No significant difference in IVR frequency was observed in other subgroups. |
Clinical Context
Diabetic macular edema represents the leading cause of vision loss in working-age adults with diabetes, developing when fluid accumulates in the macula due to breakdown of the blood-retinal barrier. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections have revolutionized DME treatment but require frequent administration, creating significant treatment burden and healthcare costs. Hypertension commonly coexists with diabetes and worsens diabetic retinopathy through mechanisms including increased vascular pressure, endothelial dysfunction, and impaired autoregulation. SGLT2 inhibitors have emerged as diabetes medications with pleiotropic benefits extending beyond glucose control to include blood pressure reduction, nephroprotection, and cardiovascular benefits. Mechanistically, SGLT2 inhibitors may benefit retinal health through reduced inflammation, osmotic diuresis effects on edema, and blood pressure lowering. This post-hoc analysis of the COMET trial explored whether SGLT2 inhibitor treatment could reduce the need for intravitreal injections in diabetic macular edema patients, particularly those with coexisting hypertension.
Clinical Pearls
- SGLT2 inhibitor treatment nearly halved the number of required intravitreal injections over 48 weeks (3.3 vs. 6.2 injections) compared to sulfonylurea in DME patients with elevated systolic blood pressure.
- The benefit was specific to hypertensive patients (OSBP ≥ 140 mmHg), with no significant difference in injection frequency observed in normotensive subgroups.
- Office diastolic blood pressure was consistently lower in the SGLT2 inhibitor group, suggesting blood pressure reduction may contribute to the injection-sparing effect.
- The finding represents a potentially important secondary benefit of SGLT2 inhibitors for diabetic patients already requiring these medications for cardio-renal protection.
Practical Application
Clinicians managing patients with diabetic macular edema requiring intravitreal injections should consider SGLT2 inhibitors as preferred glucose-lowering agents, particularly in those with coexisting hypertension. This approach may reduce injection burden while providing established cardiovascular and renal benefits. When counseling patients about diabetes medication options, the potential for reduced eye injection frequency offers additional motivation for SGLT2 inhibitor adherence. Endocrinologists, ophthalmologists, and primary care providers should communicate about medication selection to optimize both glycemic and ocular outcomes. However, the post-hoc nature of this analysis warrants caution, and SGLT2 inhibitor selection should primarily reflect established indications while considering this potential additional benefit as hypothesis-generating.
Broader Evidence Context
This study contributes to growing evidence supporting extraglycemic benefits of SGLT2 inhibitors across organ systems. Prior research suggested possible benefits for diabetic retinopathy progression, though results have been inconsistent. The finding that benefits appear concentrated in hypertensive patients provides biological plausibility, as SGLT2 inhibitors’ hemodynamic effects would be expected to have greater impact when baseline blood pressure is elevated. The results align with broader recognition that diabetes complications are driven by multiple pathophysiological factors beyond hyperglycemia alone, and that medications addressing these additional factors may provide benefits beyond glucose control. This analysis adds ocular outcomes to the cardiovascular, renal, and metabolic benefits supporting SGLT2 inhibitor prioritization in appropriate patients.
Study Limitations
- This was a post-hoc subgroup analysis of the COMET trial, not a prospectively designed study of the SGLT2 inhibitor effect on injection frequency in hypertensive patients.
- The subgroup sample sizes were not specified, raising concerns about statistical power and potential for spurious findings.
- The specific mechanism linking SGLT2 inhibitor treatment to reduced injection requirements remains speculative.
- Visual acuity outcomes and anatomic measures of macular edema were not reported, limiting assessment of whether reduced injections maintained equivalent disease control.
- Confirmation in prospective studies with larger cohorts is needed before changing clinical practice based on this finding.
Bottom Line
SGLT2 inhibitors reduce the number of required intravitreal anti-VEGF injections by approximately half in diabetic macular edema patients with elevated blood pressure, potentially decreasing treatment burden. Clinicians should consider SGLT2 inhibitors as preferred diabetes medications for DME patients, particularly those with hypertension, while awaiting prospective confirmation.
Source: Ishibashi, Ryoichi, et al. “Blood Pressure Status Modulates the Therapeutic Response to Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Macular Edema: A Post Hoc Subgroup Analysis of the COMET Trial.” Read article here.
